Prometheus Biosciences, Inc.
RXDXDelisted Jun 16, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001718852
Prometheus Biosciences, Inc. was delisted on Jun 16, 2023; its insiders filed their last Form 4 on Jun 16, 2023; 220 institutions reported holding it in 13F filings for Q1 2023, worth $4.35B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:03 PM ET
Revenue flow, FY2022
Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2022: $141.8M (2081.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 |
|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K |
| Reported | Feb 28, 2023 | Mar 9, 2022 |
| Revenue | $6.81M | $3.13M |
| Operating expenses | $152.6M | $90.9M |
| Research and development | $112.8M | $62.4M |
| Selling, general and administrative | $39.7M | $28.5M |
| Operating income | -$145.8M | -$87.8M |
| Interest expense | – | $861.0K |
| Income tax | $0 | – |
| Net income | -$141.8M | -$90.2M |
| EPS, basic | $-3.49 | $-2.88 |
| EPS, diluted | $-3.49 | – |
| Weighted shares, basic | 40.6M | – |
| Weighted shares, diluted | 40.6M | – |
| Margins and growth | ||
| Operating margin | -2141.0% | -2806.1% |
| Net margin | -2081.8% | -2882.6% |
| Revenue growth, year over year | +117.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 |
|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K |
| Reported | Feb 28, 2023 | Mar 9, 2022 |
| Cash and equivalents | $292.4M | $257.3M |
| Short-term investments | $403.3M | – |
| Accounts receivable | $1.03M | $1.08M |
| Total current assets | $708.2M | $265.4M |
| Property, plant and equipment | $3.88M | $1.45M |
| Total assets | $740.8M | $267.8M |
| Accounts payable | $762.0K | $1.15M |
| Total current liabilities | $22.8M | $16.4M |
| Total liabilities | $64.8M | $32.6M |
| Shareholders' equity | $676.0M | $235.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 |
|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K |
| Reported | Feb 28, 2023 | Mar 9, 2022 |
| Operating cash flow | -$123.3M | -$63.5M |
| Capital expenditures | $2.70M | $1.14M |
| Free cash flow | -$126.0M | -$64.6M |
| Depreciation and amortization | $629.0K | $258.0K |
| Stock-based compensation | $20.9M | $10.7M |
| Investing cash flow | -$403.8M | -$1.14M |
| Financing cash flow | $562.2M | $267.7M |
| Net change in cash | $35.2M | $203.1M |
| Ratio | ||
| Stock-based compensation, % of revenue | 306.4% | 341.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.